



**Figure S1** Sanger sequencing chromatograms of *FANCM* and *VHL* for patient RCC88's parents and brother. Genetic testing of DNA samples collected from RCC88's father (A,B), mother (C,D), and brother (E,F) revealed that none of them harbored *FANCM* or *VHL* mutations. RCC, renal cell carcinoma.

**Table S1** Genes related to germline cancer predisposition

|               |               |               |              |               |               |                |                |              |
|---------------|---------------|---------------|--------------|---------------|---------------|----------------|----------------|--------------|
| <i>AKT1</i>   | <i>BRIP1</i>  | <i>CYLD</i>   | <i>FANCC</i> | <i>HRAS</i>   | <i>MTAP</i>   | <i>PMS2</i>    | <i>SDHAF2</i>  | <i>TEK</i>   |
| <i>AKT2</i>   | <i>BTK</i>    | <i>DDR2</i>   | <i>FANCG</i> | <i>IDH1</i>   | <i>MUTYH</i>  | <i>PRKAR1A</i> | <i>SDHB</i>    | <i>TERC</i>  |
| <i>ALK</i>    | <i>CBL</i>    | <i>DICER1</i> | <i>FANCI</i> | <i>IDH2</i>   | <i>MYC</i>    | <i>PTCH1</i>   | <i>SDHC</i>    | <i>TERT</i>  |
| <i>APC</i>    | <i>CDC73</i>  | <i>DNMT3A</i> | <i>FANCL</i> | <i>JAK1</i>   | <i>MYD88</i>  | <i>PTEN</i>    | <i>SDHD</i>    | <i>TP53</i>  |
| <i>AR</i>     | <i>CDH1</i>   | <i>EGFR</i>   | <i>FANCM</i> | <i>JAK2</i>   | <i>NBN</i>    | <i>PTPN11</i>  | <i>SF3B1</i>   | <i>TSC1</i>  |
| <i>ARAF</i>   | <i>CDK4</i>   | <i>EP300</i>  | <i>FAS</i>   | <i>KIT</i>    | <i>NF1</i>    | <i>RAD50</i>   | <i>SH2D1A</i>  | <i>TSC2</i>  |
| <i>ATM</i>    | <i>CDKN1B</i> | <i>EPCAM</i>  | <i>FBXW7</i> | <i>KRAS</i>   | <i>NF2</i>    | <i>RAD51</i>   | <i>SHOC2</i>   | <i>U2AF1</i> |
| <i>AXIN2</i>  | <i>CDKN2A</i> | <i>ERBB2</i>  | <i>FGFR1</i> | <i>MAP2K1</i> | <i>NOTCH2</i> | <i>RAD51C</i>  | <i>SLX4</i>    | <i>VHL</i>   |
| <i>B2M</i>    | <i>CEBPA</i>  | <i>ERBB3</i>  | <i>FH</i>    | <i>MAP2K2</i> | <i>NPM1</i>   | <i>RAF1</i>    | <i>SMAD4</i>   | <i>WT1</i>   |
| <i>BAP1</i>   | <i>CFTR</i>   | <i>ERCC2</i>  | <i>FLCN</i>  | <i>MEN1</i>   | <i>NRAS</i>   | <i>RB1</i>     | <i>SMARCA4</i> | <i>XIAP</i>  |
| <i>BCL10</i>  | <i>CHEK2</i>  | <i>ERCC3</i>  | <i>FLT3</i>  | <i>MET</i>    | <i>NSD1</i>   | <i>RECQL4</i>  | <i>SMARCB1</i> | <i>XPO1</i>  |
| <i>BLM</i>    | <i>CREBBP</i> | <i>ERCC4</i>  | <i>FLT4</i>  | <i>MLH1</i>   | <i>NTHL1</i>  | <i>RET</i>     | <i>SMO</i>     |              |
| <i>BMPR1A</i> | <i>CSF3R</i>  | <i>ERCC5</i>  | <i>GATA2</i> | <i>MRE11</i>  | <i>PALB2</i>  | <i>RIT1</i>    | <i>SOS1</i>    |              |
| <i>BRAF</i>   | <i>CTLA4</i>  | <i>ETV6</i>   | <i>GNAS</i>  | <i>MSH2</i>   | <i>PHOX2B</i> | <i>RTEL1</i>   | <i>STAT3</i>   |              |
| <i>BRCA1</i>  | <i>CTNNB1</i> | <i>EZH2</i>   | <i>H3F3A</i> | <i>MSH3</i>   | <i>PIK3CA</i> | <i>RUNX1</i>   | <i>STK11</i>   |              |
| <i>BRCA2</i>  | <i>CXCR4</i>  | <i>FANCA</i>  | <i>HNF1A</i> | <i>MSH6</i>   | <i>PLCG2</i>  | <i>SDHA</i>    | <i>SUFU</i>    |              |

**Table S2** Clinical characteristics of patients with RCC and pathogenic mutations

| Patient ID | Sex    | Age at diagnosis (years) | Mutation gene      | Histology                    | Family history                | Recurrence or metastasis |
|------------|--------|--------------------------|--------------------|------------------------------|-------------------------------|--------------------------|
| RCC15      | Male   | 21                       | <i>VHL</i>         | ccRCC                        | Maternal aunt: VHL            | 0                        |
| RCC16      | Male   | 44                       | <i>VHL</i>         | ccRCC                        | 0                             | 0                        |
| RCC19      | Male   | 44                       | <i>VHL, RAD51C</i> | ccRCC                        | Mother: glioma                | 0                        |
| RCC40      | Male   | 36                       | <i>MUTYH</i>       | ccRCC                        | 0                             | 0                        |
| RCC63      | Male   | 39                       | <i>FANCI</i>       | Unclassified                 | Father: gastric cancer        | 0                        |
| RCC68      | Male   | 56                       | <i>FLCN</i>        | Unclassified                 | Father: gastric cancer        | 0                        |
| RCC88      | Male   | 29                       | <i>VHL, FANCM</i>  | ccRCC                        | 0                             | 1: metastasis            |
| RCC93      | Male   | 24                       | <i>RAD50</i>       | MiT family translocation RCC | 0                             | 0                        |
| RCC96      | Female | 36                       | <i>FLCN</i>        | chRCC                        | 0                             | 0                        |
| RCC109     | Male   | 62                       | <i>NBN</i>         | ccRCC                        | 0                             | 0                        |
| RCC115     | Male   | 37                       | <i>SDHB</i>        | chRCC                        | 0                             | 0                        |
| RCC121     | Female | 32                       | <i>FH</i>          | pRCC                         | Mother: endometrial carcinoma | 1: metastasis            |
| RCC122     | Male   | 24                       | <i>FH</i>          | pRCC                         | Father: RCC                   | 0                        |

RCC, renal cell carcinoma; ccRCC, clear cell renal cell carcinoma; VHL, von Hippel-Lindau; MiT, microphthalmia; chRCC, chromophobe renal cell carcinoma; pRCC, papillary renal cell carcinoma.

**Table S3** Detail on pathogenic mutations

| Study ID | Gene 1        | Variant 1               | Protein 1   | Transcript NM_#S | Pathogenicity |
|----------|---------------|-------------------------|-------------|------------------|---------------|
| RCC15    | <i>VHL</i>    | c.340G>C                | p.Gly114Arg | NM_000551        | P             |
| RCC16    | <i>VHL</i>    | c.345C>G                | p.His115Gln | NM_000551        | P             |
| RCC19    | <i>VHL</i>    | c.517_527delGAGAATTACAG | p.Glu173fs  | NM_000551        | P             |
| RCC19    | <i>RAD51C</i> | c.904+2T>C              | #           | NM_058216        | P             |
| RCC40    | <i>MUTYH</i>  | c.1214C>T               | p.Pro405Leu | NM_001128425     | P             |
| RCC63    | <i>FANCI</i>  | c.158-2A>G              | #           | NM_001113378     | P             |
| RCC68    | <i>FLCN</i>   | c.1379_1380delTC        | p.Leu460fs  | NM_001353229     | P             |
| RCC88    | <i>VHL</i>    | c.264G>A                | p.W88*      | NM_000551        | P             |
| RCC88    | <i>FANCM</i>  | c.4515+1G>C             | #           | NM_020937        | LP            |
| RCC93    | <i>RAD50</i>  | c.2165dupA              | p.E723fs    | NM_005732        | P             |
| RCC96    | <i>FLCN</i>   | c.1285dupC              | p.H429fs    | NM_001353229     | P             |
| RCC109   | <i>NBN</i>    | c.235-1G>C              | #           | NM_002485        | LP            |
| RCC115   | <i>SDHB</i>   | c.725G>A                | p.R242H     | NM_003000        | P             |
| RCC121   | <i>FH</i>     | c.A563T                 | p.N188I     | NM_000143        | P             |
| RCC122   | <i>FH</i>     | c.191dupA               | p.N64fs     | NM_000143        | P             |

#, frameshift mutation; \*, nonsense mutation; RCC, renal cell carcinoma; P, pathogenic; LP, likely pathogenic.